Vobramitamab duocarmazine: &quot;Conﬁrmed Objective Response Rate (ORR) (CR+PR), n (%) (95% CI): Vobra Duo 2.0 mg/kg q4W: 8 (17.8%); Vobra Duo 2.7 mg/kg q4W: 8 (25.0%)&quot;; Prostate cancer

vobramitamab duocarmazine (MGC018) - MacroGenics

Jun 1, 2024